Other

Ore Pharmaceuticals Inc.

Collabrx Inc.

Robert Coopersmith

Raphael Lehrer

Louis Anthony Tartaglia

David W White

Thomas M Barnes

Dominic Picarella

Scott Edward Malstrom

Methods to formulate treatments for individual cancer patients by assessing genomic and/or phenotypic differences between cancer and normal tissues and integrating the results to identify dysfunctional pathways are described.

Individualized cancer treatment

Methods to treat cancer patients, especially melanoma patients, who have BRAF mutations and have become resistant to BRAF mutant kinase inhibitors employ inhibitors of multiple receptor tyrosine kinases. In addition, methods are described for identifying pharmaceutical compositions and drugs that will be successful in treating these patients.

Method to treat melanoma in BRAF inhibitor-resistant subjects

A method for treating an inflammatory disease of the digestive tract, for example inflammatory bowel disease, in a subject comprises administering to the subject a therapeutically effective amount of a compound selected from the group consisting of (S,S)-2- [1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino]-4-methylpentanoic acid and pharmaceutically acceptable salts thereof.

Method for treating inflammatory diseases of the digestive tract

Growing community of inventors

Chestnut Hill, MA, United States of America

Robert Coopersmith